PhRMA

Hello and welcome to this week’s offering of who’s who and who’s where in the pharmaceutical outsourcing world. We kick off with news from Catalent who has made two senior appointments to support its recent expansion into China.First is Dr. Weiyan “Jackson” Zhu (left) who has joined as Catalent's Country General Manager for China. Zhu comes from Boehringer Ingelheim, where he joined as the company’s first mainland hire ever in 1998, and will play a pivotal role in Catalent’s China growth strategy.Second, we have Yufeng (Paul) Cao who becomes the new Site Operations Director, for the under-construction 31,000 sq ft Catalent (Shanghai) Clinical Trial Supplies facility, having been most recently the General Manager for Fisher Clinical Service in Beijing.And you can keep read about Catalent’s latest developments in the field of ADC technology by clickin here.To Hospira now who has named Matthew (Matt) Stober as Senior Vice President, Operations, assuming leadership for all of Hospira's pharmaceutical manufacturing operations including those at the troubled Rocky Mount facility in North Carolina.Stober has been with Hospira since 2011, coming from Johnson & Johnson, where he served as the VP and global platform leader for solids, parenterals and vaccines. He succeeds John Elliot, who is retiring at the end of the year having led the Operations organization since April 2012.F. Michael Ball, CEO at Hospira said: “In his expanded role, we're confident Matt will continue to successfully advance our dual commitment to remediate and modernize our processes and operations while delivering patient-critical products, and ultimately establish our manufacturing operations as a strategic, competitive advantage.”Next up is Eisai who has created the role of Chief Clinical Officer of Product Creation Systems and chosen Dr. Lynn Kramer to fill it.Kramer has been at Eisai since 2007 when she joined as Executive VP of Global Clinical Research, moving up to COO of Eisai Medical Research.And earlier this week we reported on how Dr. Kramer had been appointed in order to help stop late-stage failures, following the failure of its ovarian cancer candidate in phase III. Read the full story here.News from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the industry group has elected Robert Hugin, CEO of Celgene Corporation as its new Chairman, succeeding Eli Lilly’s CEO Dr. John Lechleiter.President and CEO of the PhRMA, John Castellani, said a fond farewell to Dr. Lechleiter and added: “As Bob Hugin assumes the chairmanship, I know he will continue to emphasize the importance of patient-centered policies that properly value medicines, incentivize innovation and provide a strong foundation for the millions of U.S. jobs our industry creates and supports.”Also elected were Ian Read, president and CEO of Pfizer, as chairman-elect, and Kenneth Frazier, Chairman, President and CEO of Merck & Co, as Board treasurer.Aushon BioSystems – provider of immunoassay products and services for protein biomarker discovery, development, and analysis to the pharma and biopharma industry – has announced Susan Vogt is to be the new CEO.Vogt, who turned around the fortunes of diagnostics reagents company SeraCare Life Sciences in her role of President and CEO and has previously held senior roles at Millipore Corporation, displaces former CEO and founder of the company Pete Honkanen, who will assume the role of chief operating officer and continue as a board director.Honkanen said: “Susan is joining Aushon at an exciting time, as we’re expanding to meet increasing demand for our technologies and services by pharmaceutical, biotech and other life sciences research organizations.”And finally this week, Dr. Merrilyn Datta has been appointed Chief Marketing Officer at image and data analysis solutions company Definiens.Datta comes from serving as a Senior Marketing Leader for Life Technologies (which was acquired this week by Thermo Fischer) and, according to Definiens CEO Thomas Heydler, has a “great track record in understanding the marketplace and building businesses will be invaluable for driving Definiens’ Marketing and Commercialization activities.”

PhRMA

Related news

Follow us

Webinars

Headlines

Follow us

BioPharma-Reporter

Resources